Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pregabalin in Irritable Bowel Syndrome
NCT07635394Recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Apr 2026
- Primary completion
- Apr 2026
- Countries
- 1
01
Overview
Randomised, open-label trial of pregabalin in irritable bowel syndrome (IBS) (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoints: Irritable Bowel Syndrome Severity Scoring System up to 12 weeks and Response Rate up to 12 weeks. Started Apr 2026; status: recruiting.
02
Drugs
pregabalin
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT07635394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07635394.